Khan, I.; Agarwal, P.; Assaad, N.E.; Ratan, R.; Nassif Haddad, E.F.
First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine—A Systematic Review. Cancers 2026, 18, 335.
https://doi.org/10.3390/cancers18020335
AMA Style
Khan I, Agarwal P, Assaad NE, Ratan R, Nassif Haddad EF.
First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine—A Systematic Review. Cancers. 2026; 18(2):335.
https://doi.org/10.3390/cancers18020335
Chicago/Turabian Style
Khan, Ilma, Priyal Agarwal, Nassar El Assaad, Ravin Ratan, and Elise F. Nassif Haddad.
2026. "First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine—A Systematic Review" Cancers 18, no. 2: 335.
https://doi.org/10.3390/cancers18020335
APA Style
Khan, I., Agarwal, P., Assaad, N. E., Ratan, R., & Nassif Haddad, E. F.
(2026). First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine—A Systematic Review. Cancers, 18(2), 335.
https://doi.org/10.3390/cancers18020335